Hormones and Cancer

, Volume 4, Issue 2, pp 103–110 | Cite as

Combination Chemotherapy with Cyclophosphamide, Vincristine, and Dacarbazine in Patients with Malignant Pheochromocytoma and Paraganglioma

  • Akiyo Tanabe
  • Mitsuhide Naruse
  • Kaoru Nomura
  • Mika Tsuiki
  • Aya Tsumagari
  • Atsuhiro Ichihara
Original Paper

Abstract

Choosing effective therapy for patients with malignant pheochromocytoma or paraganglioma (PPGL) is problematic and none of the options are curative. Although combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) is an established treatment option, only a limited number of case series have been reported in the literature. To determine the efficacy of CVD in patients treated at Tokyo Women's Medical University. Retrospective review of patients treated with CVD between 1989 and 2012 was conducted. Demographics, clinical presentation, imaging, and laboratory reports were reviewed and analyzed. Efficacy of CVD was ascertained from the biochemical and tumor responses. Twenty-three patients fulfilled study criteria and 6 of these were excluded due to inadequate follow-up or discontinuance by poor general condition or adverse effects. Thus, 17 cases were included in the study. The age and duration of the disease before initiation of CVD were 54.7 ± 12.0 years and 9.1 ± 8.1 years, respectively. The follow-up period after initiation of CVD ranged from 12 to 192 months (median, 60 months). Complete or partial biochemical and/or partial tumor response was achieved in 47.1 % (responders). No significant biochemical or tumor response was seen in 23.5 % and deterioration in biochemical and tumor outcomes was seen in 29.4 % (non-responders). No patient showed complete biochemical and tumor responses. In responders, these effects were documented within 4 months after initiation of CVD with a progression-free survival of 31 to 60 months (median, 40 months). Age at the first diagnosis with PPGL was younger (P < 0.05) and the lag time to eventual diagnosis of malignant disease was longer (P < 0.05) in responders than those in non-responders. The responders had improvements in hypertension and impaired glucose tolerance. Although CVD chemotherapy is not curative for patients with malignant PPGL, it does provide approximately half of the patients with biochemical, tumor, and hypertension benefits.

References

  1. 1.
    O’Riordain DS, Young WF Jr, Grant CS, Carney JA, van Heerden JA (1996) Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 20(7):916–921PubMedCrossRefGoogle Scholar
  2. 2.
    Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB (2007) The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr-Relat Cancer 14(3):569–585PubMedCrossRefGoogle Scholar
  3. 3.
    Mishra AK, Agarwal G, Kapoor A, Agarwal A, Bhatia E, Mishra SK (2000) Catecholamine cardiomyopathy in bilateral malignant pheochromocytoma: successful reversal after surgery. Int J Cardiol 76(1):89–90PubMedCrossRefGoogle Scholar
  4. 4.
    Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC (1997) The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 20:648–658PubMedGoogle Scholar
  5. 5.
    Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P (2009) Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 27(25):4162–4168PubMedCrossRefGoogle Scholar
  6. 6.
    Lehnert H, Mundschenk J, Hahn K (2004) Malignant pheochromocytoma. Front Horm Res 31:155–162PubMedCrossRefGoogle Scholar
  7. 7.
    Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr (1997) Metyrosine and pheochromocytoma. Arch Intern Med 157(8):901–906PubMedCrossRefGoogle Scholar
  8. 8.
    Averbuch SD, Steakley CS, Young RC et al (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109(4):267–273PubMedGoogle Scholar
  9. 9.
    Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K, Fojo T (2008) Treatment of malignant pheochromocytoma and paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113(8):2020–2028PubMedCrossRefGoogle Scholar
  10. 10.
    Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T, Takano K (2009) Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab 94(8):2850–2856PubMedCrossRefGoogle Scholar
  11. 11.
    Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S, Jimenez C (2012) Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 118(11):2804–2812PubMedCrossRefGoogle Scholar
  12. 12.
    Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG, Deandreis D, Baudin E, Jimenez C (2012) Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 97(11):4040–4050PubMedCrossRefGoogle Scholar
  13. 13.
    Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB (2009) Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 41(9):697–702PubMedCrossRefGoogle Scholar
  14. 14.
    Ma BB, Hui EP, Mok TS (2010) Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 11(1):75–84PubMedCrossRefGoogle Scholar
  15. 15.
    Sato H, Kanai G, Hirabayshi K, Kajiwara H, Itoh J, Osamura RY (2010) L157X nonsense mutation of the succinate dehydrogenase subunit B gene in a Japanese patient with right paraaortic paraganglioma. Endocrine 38(1):18–23PubMedCrossRefGoogle Scholar
  16. 16.
    Oishi Y, Nagai S, Yoshida M, Fujisawa S, Sazawa A, Shinohara N, Nonomura K, Matsuno K, Shimizu C (2010) Mutation analysis of the SDHB and SDHD genes in pheochromocytomas and paragangliomas: identification of a novel nonsense mutation (Q168X) in the SDHB gene. Endocr J 57(8):745–750PubMedCrossRefGoogle Scholar
  17. 17.
    Kodama H, Iihara M, Nissato S, Isobe K, Kawakami Y, Okamoto T, Takekoshi K (2010) A large deletion in the succinate dehydrogenase B gene (SDHB) in a Japanese patient with abdominal paraganglioma and concomitant metastasis. Endocr J 57(4):351–356PubMedCrossRefGoogle Scholar
  18. 18.
    Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H (2007) Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92:1217–1225PubMedCrossRefGoogle Scholar
  19. 19.
    Patel SR, Winchester DJ, Benjamin RS (1995) A 15-year experience with chemotherapy of patients with paraganglioma. Cancer 76(8):1476–1480PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Akiyo Tanabe
    • 1
  • Mitsuhide Naruse
    • 3
  • Kaoru Nomura
    • 1
    • 2
  • Mika Tsuiki
    • 1
    • 4
  • Aya Tsumagari
    • 1
    • 3
  • Atsuhiro Ichihara
    • 1
  1. 1.Department of Medicine IITokyo Women’s Medical UniversityTokyoJapan
  2. 2.Department of General Medicine Tokyo Women’s Medical UniversityTokyoJapan
  3. 3.Clinical Research Institute, Division of Endocrinology, Metabolism and HypertensionNational Hospital Organization Kyoto Medical CenterKyotoJapan
  4. 4.Department of Endocrinology and MetabolismNational Hospital Organization Kyoto Medical CenterKyotoJapan

Personalised recommendations